Amylyx Pharmaceuticals Current Assets

The latest current assets for AMLX is $260M as of June 2026. That compares with $190M in the prior-year period — up 37.2% year over year. Investors often review this figure alongside Amylyx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMLX's current assets moved from $190M to $260M — a 37.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amylyx Pharmaceuticals's operating scale or balance-sheet position.

A current assets figure of $260M for AMLX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AMLX's current assets ($260M), review year-over-year change from $190M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.